Despite advances in revascularization techniques, limb salvage and relief of pain cannot be achieved in many diabetic patients with diffuse peripheral vascular disease. Our objective was to determine the effect of intramuscular administration of phVEGF 165 (VEGF gene containing plasmid) on Critical Limb Ischemia (CLI) compared to placebo (0.9% NaCl). A double blind placebo controlled study was performed in 54 adult diabetic patients with CLI. The primary end point was the amputation rate at 100 days. Secondary end points were a 15% increase in pressure indices (ABI/TBI), clinical improvement (skin, pain and quality of life (QOL)) and safety.
Introduction
Critical Limb Ischemia (CLI) is a disease manifested by sharply diminished blood flow to the legs; it is the most common cause of non-traumatic amputation in diabetes. The condition is responsible for 70% of the 150 lower limb amputations per million in the population. 1 Although a combination of neuropathy, obstructive macro-vascular disease and/or micro-vascular changes is usually pivotal in the development of the diabetic foot, the contribution of micro-vascular occlusions is predominant in the diabetic subgroup with CLI and is not accessible for surgical revascularization. Amputation is unavoidable in 0.7 per 10.000 patients with diabetes mellitus. 2;3 Among CLI patients who have already had all possible surgical revascularization done, amputation is inevitable in approximately half. 2;4 The median survival of patients with CLI is approximately 3 years. 5;6 The quality of life during this period is limited. 7 New methods of treatment of CLI have been recently explored. Pre-clinical studies have defined a role for vascular growth factors in neoangiogenesis in animal models of peripheral ischemia. 8;9 The most potent angiogenic factor affecting endothelial cell proliferation is VEGF 165 , an endothelial cell specific mitogen from a family of six isoforms. However as a protein its short half life and its effects on vascular permeability have limited its clinical application. 10;11 Its use in the form of gene therapy, either as naked plasmid or in a viral vector, has been reported only in small studies showing beneficial clinical effects in some but not all trials. [12] [13] [14] [15] [16] [17] If the clinical benefits originally seen in the studies by Isner and Baumgartner, using intramuscular injections of naked VEGF 165 plasmid DNA (phVEGF 165 ) could be reproduced in a well-defined patient group in a randomized study, this would, in our opinion, redefine the place of this form of gene therapy for CLI. The primary aim of our study was to assess the effects of phVEGF 165 , in addition to maximal standard treatment, on the amputation rate in a placebo-controlled randomized study, in a group of diabetic patients with CLI. The secondary objectives were hemodynamic improvement, clinical improvement and safety.
Materials and methods

Study design
The study was a two-center, randomized, double blind, controlled study comparing phVEGF 165 with placebo (0.9% NaCl), with limb survival and/or predefined changes in pressure indices as primary measure of effect. The study was approved by the Centrale Commissie Mensgebonden Onderzoek (CCMO: Central Medical Ethics Committee) in the Netherlands and performed in two centers (University Medical Center Groningen, Leiden University Medical Center, The Netherlands).
Patients received phVEGF 165 or placebo by computerized block randomization, without stratification or matching, performed by the pharmacy of the University Medical Center Groningen. Patients were assigned either to receive 2000 μg phVEGF 165 or placebo on day 0 and day 28. Follow-up evaluation was performed on days 7, 14, 35, 42, 72 and 100, with registration of clinical symptoms, wound status and hemodynamic condition. In addition routine hematology, chemistry, urinalysis, anti-double-stranded DNA (dsDNA) antibodies and circulating VEGF and phVEGF 165 levels were determined. Ophthalmologic examination was performed before treatment, on day 28 and at the conclusion of the study.
Patients
Patients were recruited from a large number of academic and non-academic hospitals in the Netherlands by approaching their departments of vascular surgery.
Patients with either type I or type II diabetes mellitus established according to current American Diabetes Association (ADA) criteria were eligible. Evidence of critical limb ischemia had to be present including rest pain and/or ulcers that had not healed for a minimum of 2 weeks despite conventional therapy. Patients with compressible vessels had to have a resting ankle systolic blood pressure <50 mmHg, or toe systolic blood pressure <30 mmHg in the affected limb. Patient had to be unsuitable candidates for surgical or percutaneous revascularization as judged after contrast angiography by the vascular surgeon and intervention radiologist. Further exclusion criteria included active proliferative diabetic retinopathy, a history of malignancy, severe co-morbidity and/or compromising co-medication. Patients gave written informed consent for their participation.
Gene product and administration
The plasmid containing the human VEGF 165 gene (Genbank accession no. AB021221) which is transcriptionally regulated by the cytomegalovirus promotor/enhancer, was manufactured under Good Manufacturing Practices guidelines according to Isner et al. and Sarkar et al. 13; 18 The plasmid was a gift from J.M. Isner, and was the same as has been used by his group. Patients received four aliquots each containing 500 Pg phVEGF 165 diluted in a volume of 1.0 mL 0.9% NaCl (total 2000 Pg) injected intramuscularly (26-gauge needle) into the thigh (two aliquots) and calf muscles (two aliquots) of the most ischemic limb. The injection sites were arbitrarily selected according to available muscle mass as described in the protocol from Baumgartner et al. 12 This procedure was repeated once at 4 weeks, resulting in a total of 4000 μg of phVEGF 165 being administered into the ischemic leg. In a matching placebo procedure patients received four times 1.0 mL 0.9% NaCl. No difference between the phVEGF 165 and placebo could be seen or felt by the physician who performed the injection.
Procedures
Ischemic skin defects were copied onto a transparent sheet to calculate the ulcer surface area. In addition, ischemic skin defects were documented by color photography. Assessment of ischemic rest pain was performed using a visual analogue scale (VAS) for pain scores and by the documentation of the daily use of analgesics.
Ankle pressure was measured according to conventional procedures with the patient at rest in a semisupine position. Measurements were performed by an experienced vascular technician using an 8-MHz Doppler ultrasound system (Parks Medical Electronics, Aloha, OR) with the occluding cuff around the ankle, unless wounds extended to the proximal foot or ankle, in which case the cuff was placed around the upper leg. Toe pressures were measured after at least 10 minutes of warming using a photoplethysmographic diode on the pulp area and a small occluding cuff at the base of the toe. The pressure at which pulsatile signals reappeared upon cuff release was noted. If a skin defect was present in digit I or II, toe pressures were not measured. The ankle-to-brachial index (ABI) and the toe-to-brachial index (TBI) were calculated as the quotient of the absolute ankle or toe pressures, and the simultaneously measured brachial pressure.
In accordance with the literature (Matzke et al, 2003) our trained vascular technicians scored a coefficient of variation of ABI in patients with CLI of 3.2% and the inter observer difference did not exceed this. Quality of life assessment using the RAND-36 questionnaire 19 ;30 was performed to determine if a clinical response had a positive effect on the Quality of life.
20
Ophthalmologic examination at baseline and at each subsequent follow-up visit included best corrected visual acuity measurement and intraocular pressure, slitlamp biomicroscopy, indirect ophthalmoscopy and fundus photography. Fluorescein angiography (with intravenous administration of 5 mL of 10% sodium fluoride) was performed at baseline and after 100 days of the study. Diabetic retinopathy was classified as follows: no retinopathy, background retinopathy, preproliferative diabetic retinopathy or proliferative diabetic retinopathy. Systemic VEGF levels were determined by Quantikine human VEGF enzyme-linked immunosorbent assay (ELISA) (R&D Systems Inc. Minneapolis, MN). Whole blood (in citrate-theophyoline-adenosine-dipyridamole (CTAD) tube) was diluted three times with phosphate-buffered saline (PBS). To damage the membranes the cellular suspension was frozen and thawed twice. The serum (coagulation for at least 1 hour) samples were centrifuged for 15 minutes at 3000 X g at room temperature. Samples were stored in aliquots at -80 0 C until analysis. Results were compared with a standard curve of human VEGF, with a detection limit of 5 pg/ml. Analysis of systemic phVEGF 165 in whole blood was performed by polymerase chain reaction (PCR) after isolation of the DNA according to the Boom procedure. 21 This method allowed a detection limit of 2.0 fg phVEGF 165 per microliter blood.
Definitions of measures of effect
Response was defined as limb survival, hemodynamic improvement of ABI or TBI at two different time points, or improvement of skin ulcers and rest pain. Limb survival was defined as the absence of a major amputation. A major amputation is an amputation proximal to the level of the ankle. A hemodynamic improvement is defined as an absolute increase of >15 % in ABI or TBI. This increase is considered as a significant clinically relevant improvement. [22] [23] [24] Ischemic wound response was defined as a decrease in wound surface area of >60%. Improvement of pain was defined as >50% decrease in pain scores as assessed using the VAS at various time points (baseline to day 28, 72, and day 100). Safety was assessed by incidence and severity of adverse events: vital signs (i.e. fever, or hypotension defined as systolic blood pressure <90 mmHg) during and after administration of intramuscular injections, diabetic retinopathy, edema, anti-dsDNA (Farr assay), proteinuria, teleangiectasia, circulating phVEGF 165 and analysis of survival.
Statistical analysis
The target number of patients was determined on the basis of the expected incidence of amputations in the control group and the foreseen success rate of the intervention. The incidence of amputation in diabetic patients is 0.7/10.000. Data from studies by Klevsgard et al. 4 and da Silva et al. 2 give indirect indications of the incidence of amputation in end-stage CLI. In both studies the patients were still amenable to surgical intervention, and therefore constituted an earlier disease state than our patients. Nevertheless, amputation occurred in 40% of the patients in the da Silva study and in at least 40% in the Klevsgard study. We therefore projected an amputation rate of 50% in the control group. The expected success rate of the intervention was estimated from the available clinical data on VEGF gene therapy at that time. 12-14;25 About three-quarters of these patient were either rescued from imminent amputation or showed substantial improvement in parameters such as ABI, which can be considered directly relevant to the chance of avoiding amputation in the near future. On the basis of this success rate, 54 patients were considered to be needed to be able to demonstrate the expected reduction from 50 to 25% in the amputation rate (power 0.85, p=0.05). Baseline characteristics and response rate comparisons between the groups were analyzed using the chi-square test, corrected for continuity. For continuous variables the independent T-test was used. For QOL analysis changes within the group between baseline, 28 day and 100 day assessments were analyzed by Friedman test. Differences between the groups were measured using the Mann-Whitney U test. The same tests were used for analysis of laboratory parameters. Survival analysis was calculated according to Kaplan-Meier test. A p value <0.05 was considered statistically significant.
Results
In the period between February 2000 and January 2004, 97 patients were screened: 54 were found to be eligible and were randomized. Patient refusal and surgical alternatives were the most common exclusion grounds. Five patients were excluded because of proliferative diabetic retinopathy. Basic demographic characteristics were similar in both groups (see Table 1 ). 
Duration of leg ischemia symptoms
Months (mean, range) 9.5 (1-48) 8.6 (1-30) Prior vascular reconstruction / Percutaneous angioplasty 10 10 Prior amputation 3 3 Abbreviations: ID, insulin dependent; HbA1c, hemoglobin A1c; CAD, coronary artery disease. Data are numbers, unless otherwise stated. No significant differences were found (chi-square corrected for continuity, for continuous variables the independent T-test was performed). 1) Surgical removal of debris occurred in 15% of the patients in both groups within four weeks before treatment.
Table 1 Baseline characteristics
Treatment results
All patients were evaluated for all end points (pressure, skin ulcers, and pain). Usually wounds precluded measuring of pressure. An overview of responding patients and treatment results are summarized in Table 2A and B. A major amputation was performed in six of the control patients and in three of the phVEGF 165 -treated patients (p=NS). The mean time to amputation was 78 days in the phVEGF 165 -treated patients and 25.5 days in the control arm (p=0.11). The amputation rate in the control group was therefore 25%. For hemodynamic assessment 16 patients were not evaluable, because of incompressible vessels or extensive ulceration that made ankle or toe pressure assessment not feasible. An absolute increase of >15% in ABI or TBI on at least two time points occurred in 7 of 21 evaluable phVEGF 165 patients. In the control group only one patient of the 17 evaluable patients showed a hemodynamic increase of >15%. phVEGF 165 treatment tended to improve pressure parameters (p=0.05). Median time to improvement (day 0 to first increase of >15%) was 4 weeks and this improvement was still present at day 100. Skin ulcers were evaluated in all 38 patients with ulcers (see Table 1 ). Of 21 evaluable phVEGF 165 patients there were 7 responders, whereas none of the control patients showed an improvement of ulceration (p=0.01). Ulcer healing of more than 60% occurred after a median 5 weeks after injection and was still present on day 100 (Figure 1 ). One phVEGF 165 treated patient presented with ischemic ulceration in both legs. Skin ulcers in the injected leg, as well as the opposite leg showed clinically relevant improvement with a >60% decrease in ulcer surface. In 7 patients there was no rest pain. Five patients were not evaluated for pain because of minor surgical intervention, that is, amputation of the toe or extensive debridement of skin defects, shortly before the first intramuscular injection. In 10 patients, who could not understand the VAS scale, pain data were incomplete. However in five of these patients it could be determined on the basis of anamnesis and use of pain medication that there was no change. Two of 11 control patients had a >50% decrease in pain score versus 5 of 21 phVEGF 165 patients (p=NS). Overall there were 17 responding patients ( Table 2) . As some patients responded in more than one category (hemodynamic, skin ulcers or pain) there were a total of 22 responses. In the phVEGF 165 treated patients there were four patients with more than one category improved; in the control group, none. Three responders received placebo and 14 received phVEGF 165 . The advantage for phVEGF 165 compared with placebo was significant (p=0.003).
Quality of life assessment
Quality of life (QOL) assessment (see Table 3 ) was performed in 46 patients; 8 patients did not provide sufficient data. At baseline the only imbalance between the control and phVEGF 165 treated group was in health experience (data not shown).
Overall there was no improvement in QOL with phVEGF 165 treatment as compared to placebo treatment (data not shown). However, clinical and/or hemodynamic responders showed improved physical functioning, social functioning and health change as compared to nonresponders (p=0.002, p=0.045, and p=0.05 respectively). 
VEGF blood levels
The median serum VEGF level at baseline was 321 pg/ml (range, 53-1677 pg/ml) in control patients and 275 pg/ml (range, 53-1103 pg/ml) in phVEGF 165 treated patients (p=NS). The median whole blood VEGF level were 846 pg/ml (range, 199-1963 pg/ml) in the control group compared with 911 pg/ml (range, 365-1843 pg/ml) in the phVEGF 165 patients (p=NS). There was no transient increase in circulating VEGF after intramuscular treatment in either group. In individual patients 10% showed a 50% increase in VEGF level within 14 days of intramuscular injection in both groups.
Safety
PhVEGF 165 was well tolerated (Table 4) . No changes in systolic or diastolic blood pressure were observed. Edema was already present before injection in 11 patients of the control group and in 10 patients of the phVEGF 165 group. The edema increased in these 21 patients and new formation of edema occurred in 3 phVEGF 165 treated patients, and in four control patients (p=NS). New teleangiectasias were found in two patients: in one phVEGF 165 treated patient and one control patient. They occurred within 14 days after intramuscular injection, and persisted thereafter. Otherwise unexplained hypoglycemia (<3 mmol/liter) occurred in two phVEGF 165 treated patients in the first 2 to 3 weeks after intramuscular injection. Microalbuminuria (30, to a maximum of 300, mg/day) was detected in the majority of the 37 patients measured, and remained stable during follow-up in both groups without significant variation. In the phVEGF 165 -treated group no anti-dsDNA was detected. Analysis for the presence of phVEGF 165 in peripheral blood was possible in 20 phVEGF 165 patients; phVEGF 165 could actually be detected in 4 patients within the first 3 days after injection. There were four deaths within the follow-up period of 100 days. These deaths were not related to the treatment: two patients died in the phVEGF 165 treated group and 2 patients in the placebo group. In the phVEGF 165 treated group one patient died of sepsis, 3 weeks after a major amputation of the leg, and one patient died in the postoperative period after a total hip replacement. In the control arm 2 patients died: one patient died 2 weeks after a major amputation, and the other patient died of protracted Staphylococcus aureus sepsis caused by an infected hip prosthesis. One-year survival in non-amputated patients in the control and phVEGF 165 -treated groups was, respectively, 60 and 84% (p=NS). The progression from no diabetic retinopathy to minimal background retinopathy (less than 10 red dots) was 15% in both treatment arms; no progression to proliferative diabetic retinopathy was seen. Other ophthalmological parameters remained stable during the whole study. There was no diagnosis of cancer.
Control (n=27)
PhVEGF
Discussion
Once the options for surgical intervention have been exhausted, few treatment alternatives remain for patients with end-stage CLI. In this study we did not meet the primary end point of a reduced amputation rate. We did, however, demonstrate that intramuscular injections of the naked plasmid DNA encoding VEGF 165 (phVEGF 165 ) significantly improved wound healing and reduced hemodynamic insufficiency compared with placebo. Importantly, in the responders these clinical improvements resulted in improved physical functioning (mobility, and daily activities such as washing, dressing and cleaning) and improved social functioning as detected by the RAND-36 questionnaire for QOL. Therefore "response" as defined in this study seems to be a meaningful notion. Despite the rigorous entry criteria applied, a placebo effect, either a symptom of natural variation and fluctuation in the degree of ischemia, or an effect of intensified care in the study patients, is undeniable as three of the responders were among the placebo-treated patients. In contrast, significant clinical improvement was seen in 14 of the 27 patients treated with naked plasmid DNA. This 50% success rate is in agreement with the pioneering study of Baumgartner et al. 12 Our results further confirm more recent data from studies in Chinese and Korean cohorts, in which an even higher response rates were achieved. 15;17 On the other hand, no clinical improvement was found in a study by Makinen and co-workers, although angiography measurements suggested improvement. 16 However, their patient group was not well defined and the plasmid was given intra-arterially instead of intramuscularly. Table 5 shows an overview of gene therapy studies in patients with CLI, treated with a plasmid containing VEGF 165 . The amputation rate in these series confirms ours (approximately 16%). In a phase II randomized, double blind controlled study of patients with intermittent claudication, VEGF 121 in an adenoviral vector was administered as a single intramuscularly injection, instead of phVEGF 165 . 26 In contrast to our study, this trial was not associated with an increase in ABI/TBI, improved wound healing or improved QOL. Besides the difference in study design, a difference in local VEGF concentration might be responsible for the observed difference in clinical results.
There is a major difference between these VEGF proteins as VEGF 121 diffuses easily while VEGF 165 binds to matrix components. Our primary aim was limb salvage, or a reduction in major amputation rate; however our estimate of expected amputations (50%) proved to be too pessimistic. The small number of amputations (17%) that actually occurred ultimately precludes any conclusions about this form of gene therapy regarding potential treatment efficacy in terms of limb salvage. Although improvements in surgery have in the past influenced the need for amputation in this patient group 27 , this cannot have played a role among our patients who were beyond surgical intervention. In a more recent Danish study, a further decline in amputations followed the institution of dedicated multidisciplinary foot clinics. 28 As these clinics have also been instituted in the Netherlands, they may be partly responsible for the low incidence of amputations in our patient cohort. An alternative possibility would be that our patient cohort has been included too early in the course of their disease. This explanation is unlikely in view of the rigorous entry criteria, the limited median survival of the whole group, and the severely affected QOL at the beginning of the study. In a cohort of ambulant diabetic patients in the same hospital area with early peripheral artery disease 29 , the QOL scores were between 50 to 90% in relevant domains compared to 5 to 50% in the present study. In contrast to other studies, but in agreement with a phase I study in non-diabetic patients and the phase II study by Makinen and co-workers, we found no evidence of increased levels of systemic VEGF. 12;14-17 Therefore, discussion concerning whether local or systemic effects, or both, contribute to the response remains open. There do not seem to be easy ways to clarify this problem in the clinical situation. Although amputation material is occasionally available for analysis, results would be unlikely to give information about successful interventions. Biopsies to clarify the mechanism in responding patients who have had severely compromised wound repair are undesirable. Intramuscular phVEGF 165 was well tolerated. With the possible exception of hypoglycemia in two patients, no side effects occurred. This small randomized study could serve to regenerate interest in the angiogenic approach in CLI. In a disease with an intrinsic placebo effect, the first priority obviously would be to confirm these results in a larger study. The number of patients to be studied should permit rather low numbers of amputations in the control group, between 10 and 15%. Also the use of completely different end points, preferable of a non-invasive nature, should be considered. In such a study the theoretical possibility of a therapeutic effect of an empty plasmid could also be excluded. Improvements in the treatment scheme would thereafter include changes in the duration of treatment, the possible combined application of multiple effective genes, and the use of alternative transfection methods.
